Emerald Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Emerald Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$832K	Sell	24,548 -9,741	-28%	-$324K	0.02%	157
2026 Q1	$1.03M	Hold	34,289	–	–	0.03%	144
2025 Q4	$1.07M	Sell	34,289 -1,537	-4%	-$37.9K	0.03%	136
2025 Q3	$724K	Sell	35,826 -5,209	-13%	-$91.5K	0.02%	162
2025 Q2	$688K	Sell	41,035 -6,062	-13%	-$97.8K	0.03%	161
2025 Q1	$724K	Sell	47,097 -2,653	-5%	-$47.4K	0.03%	145
2024 Q4	$1.1M	Sell	49,750 -35,809	-42%	-$651K	0.04%	133
2024 Q3	$1.54M	Sell	85,559 -1,188	-1%	-$20.8K	0.06%	125
2024 Q2	$1.41M	Sell	86,747 -16,739	-16%	-$258K	0.06%	129
2024 Q1	$1.46M	Buy	103,486 +37,272	+56%	+$470K	0.06%	129
2023 Q4	$691K	Sell	66,214 -1,238	-2%	-$11.6K	0.03%	166
2023 Q3	$688K	Buy	+67,452	New	+$628K	0.03%	159

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Emerald Advisers's TEVA Position: Q2 2026 in Review

Emerald Advisers reduced its Teva Pharmaceuticals (TEVA) stake by 28% in Q2 2026, selling an estimated $324K and leaving 24,548 shares worth $832K. The position accounts for 0.02% of the portfolio, ranked #157.

Emerald Advisers first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.54M in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Emerald Advisers held 24,548 shares of Teva Pharmaceuticals worth $832K as of Q2 2026.
Emerald Advisers sold 9,741 Teva Pharmaceuticals shares in Q2 2026, an estimated $324K.
Teva Pharmaceuticals made up 0.02% of Emerald Advisers's portfolio in Q2 2026, its #157 holding.
Emerald Advisers first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Emerald Advisers's Teva Pharmaceuticals position peaked at $1.54M in Q3 2024.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.